AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7652966 — intervention group
Group type: COMPARATOR
Intervention: No thrombolytic therapy (Control)
Number of subjects: 1881
Study 7652966 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 1881
Study 2540099 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole
Number of subjects: 20
Study 2540099 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory agents (NSAIA)
Number of subjects: 20
Study 2540099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2540099 — intervention group
Group type: COMPARATOR
Intervention: Untreated RA patients
Number of subjects: 20
Study 352139 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (CDC)
Number of subjects: 0
Study 352139 — intervention group
Group type: COMPARATOR
Intervention: Chenodeoxycholic acid (CDC) and phenobarbital (PB)
Number of subjects: 0
Study 352139 — intervention group
Group type: COMPARATOR
Intervention: Control group (calcified gallstones)
Number of subjects: 0
Study 31967501 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Learning Reconstruction (DLR)
Number of subjects: 59
Study 31967501 — intervention group
Group type: COMPARATOR
Intervention: Iterative Reconstruction (IR)
Number of subjects: 59
Study 31967501 — intervention group
Group type: COMPARATOR
Intervention: Filtered Back-Projection (FBP)
Number of subjects: 59
Study 31967501 — intervention group
Group type: COMPARATOR
Intervention: Adaptive Iterative Dose Reduction (AIDR) 3D
Number of subjects: 59
Study 30095550 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.4 mg/kg)
Number of subjects: 100
Study 30095550 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 100
Study 29753000 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postoperative ambulation
Number of subjects: 120
Study 29753000 — intervention group
Group type: COMPARATOR
Intervention: Control group (no early ambulation)
Number of subjects: 120
Study 26812997 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback labelled with the feedback provider's profession (two comments correctly labelled and two incorrectly labelled)
Number of subjects: 45
Study 26812997 — intervention group
Group type: EXPERIMENTAL
Intervention: Unlabelled feedback where participants guessed the provider's profession
Number of subjects: 45
Study 24717713 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealants/PRRs
Number of subjects: 534
Study 23740915 — intervention group
Group type: EXPERIMENTAL
Intervention: VRS with instructor feedback (DSF)
Number of subjects: 43
Study 23740915 — intervention group
Group type: EXPERIMENTAL
Intervention: VRS without instructor feedback (DS)
Number of subjects: 43
Study 23740915 — intervention group
Group type: COMPARATOR
Intervention: No VRS features (NDS)
Number of subjects: 43
Study 20429800 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol
Number of subjects: 147
Study 20429800 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol
Number of subjects: 147
Study 20429800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 17890456 — intervention group
Group type: EXPERIMENTAL
Intervention: BEACOPP regimen
Number of subjects: 38
Study 16827813 — intervention group
Group type: EXPERIMENTAL
Intervention: R216073 (2,000 mg)
Number of subjects: 20
Study 12783595 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab 3 mg/kg every 28 days
Number of subjects: 0
Study 12783595 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab 6 mg/kg every 28 days
Number of subjects: 0
Study 12783595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12783595 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab (both doses)
Number of subjects: 0
Study 12783595 — intervention group
Group type: COMPARATOR
Intervention: All groups (including placebo)
Number of subjects: 0
Study 10617734 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention emphasizing health risks of ETS for children
Number of subjects: 479
Study 10617734 — intervention group
Group type: COMPARATOR
Intervention: Routine smoking cessation advice
Number of subjects: 479
Study 10617734 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving safety information
Number of subjects: 479
Study 8751632 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen
Number of subjects: 66
Study 1400057 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen
Number of subjects: 24
Study 1400057 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 24
Study 1400057 — intervention group
Group type: COMPARATOR
Intervention: No medication (control)
Number of subjects: 24
Study 1400057 — intervention group
Group type: COMPARATOR
Intervention: All groups (including ibuprofen, pentoxifylline, and control)
Number of subjects: 24
Study 2867712 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 0
Study 2867712 — intervention group
Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 0
Study 30840918 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligofructose-enriched inulin (Synergy 1) 10 g for three months
Number of subjects: 34
Study 30840918 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin) for three months
Number of subjects: 34
Study 30840918 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Synergy 1 and placebo)
Number of subjects: 34
Study 30081962 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinhala version of Menopause Rating Scale (MRS)
Number of subjects: 166
Study 26690291 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone (BUP)
Number of subjects: 95
Study 26690291 — intervention group
Group type: COMPARATOR
Intervention: DETOX
Number of subjects: 95
Study 25912670 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluative conditioning intervention (n = 22)
Number of subjects: 39
Study 25912670 — intervention group
Group type: COMPARATOR
Intervention: Delayed waitlist control condition (n = 17)
Number of subjects: 39
Study 22492565 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural self‐help treatment (online)
Number of subjects: 74
Study 22492565 — intervention group
Group type: COMPARATOR
Intervention: Obese BED individuals
Number of subjects: 74
Study 18586995 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based referral care management (TBR-CM) intervention, which included usual care plus one or two brief motivational telephone sessions.
Number of subjects: 113
Study 18586995 — intervention group
Group type: COMPARATOR
Intervention: Usual care, which consisted of scheduling a behavioral health care appointment followed by a letter and reminder by telephone.
Number of subjects: 113
Study 15849531 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive monthly counseling sessions about condom use (8 sessions)
Number of subjects: 966
Study 15849531 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after the trial
Number of subjects: 966
Study 15849531 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up survey
Number of subjects: 966
Study 12444179 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein-D-subunit vaccine
Number of subjects: 2714
Study 12444179 — intervention group
Group type: COMPARATOR
Intervention: Control injection
Number of subjects: 2714
Study 10083699 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive dissemination method (mailout enhanced by personal contact with midwifery facilitators)
Number of subjects: 23
Study 10083699 — intervention group
Group type: COMPARATOR
Intervention: Simple dissemination method (mailout of the 'Fresh Start' program)
Number of subjects: 23
Study 7552591 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mcg/kg loading dose of diamorphine
Number of subjects: 27
Study 7552591 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mcg/kg loading dose of diamorphine
Number of subjects: 27
Study 3065875 — intervention group
Group type: EXPERIMENTAL
Intervention: Dydrogesterone 10 mg twice daily from the 12th day until onset of the following menstrual period
Number of subjects: 161
Study 3065875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 3065875 — intervention group
Group type: EXPERIMENTAL
Intervention: Dydrogesterone
Number of subjects: 161
Study 30305148 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological Support for Personality (PSP)
Number of subjects: 0
Study 30305148 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 0
Study 28407415 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 28
Study 28407415 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 28
Study 28407415 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide + Insulin glargine
Number of subjects: 28
Study 25853384 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical administration of radiocolloid and blue dye (Group 1)
Number of subjects: 188
Study 25853384 — intervention group
Group type: COMPARATOR
Intervention: Subserosal injection of blue dye (Group 2)
Number of subjects: 188
Study 23483175 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding promotion intervention
Number of subjects: 13479
Study 23483175 — intervention group
Group type: COMPARATOR
Intervention: Usual practices (Control)
Number of subjects: 13479
Study 21939798 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamed nailing up to 12 mm with an 11 mm tibial nail (n: 50)
Number of subjects: 100
Study 21939798 — intervention group
Group type: COMPARATOR
Intervention: Minimally reamed nailing up to 10 mm with a 9 mm tibial nail (n: 50)
Number of subjects: 100
Study 21939798 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamed nailing
Number of subjects: 100
Study 21939798 — intervention group
Group type: COMPARATOR
Intervention: Minimally reamed nailing
Number of subjects: 100
Study 19127025 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass fiber-reinforced composite resin (GFRCR) space maintainer
Number of subjects: 30
Study 19127025 — intervention group
Group type: COMPARATOR
Intervention: Band-and-loop space maintainer
Number of subjects: 30
Study 20593635 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive Periochip (chlorhexidine) with scaling and root planing
Number of subjects: 50
Study 20593635 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing only
Number of subjects: 50
Study 16139697 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional method (T)
Number of subjects: 122
Study 16139697 — intervention group
Group type: COMPARATOR
Intervention: Simplified method (S)
Number of subjects: 122
Study 11901328 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist protector
Number of subjects: 721
Study 11901328 — intervention group
Group type: COMPARATOR
Intervention: Control group (unprotected)
Number of subjects: 721
Study 11901328 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist protector (per-protocol analysis)
Number of subjects: 721
Study 9776411 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day
Number of subjects: 127
Study 9776411 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg/day
Number of subjects: 127
Study 9776411 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg/alternate days
Number of subjects: 127
Study 9776411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 7531109 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg twice daily for 3 days)
Number of subjects: 0
Study 7531109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2904755 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (mean final daily dose 2.5 mg)
Number of subjects: 72
Study 2904755 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine (mean final daily dose 13.9 mg)
Number of subjects: 72
Study 12189744 — intervention group
Group type: EXPERIMENTAL
Intervention: Permixon 320 mg per day
Number of subjects: 704
Study 12189744 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.4 mg per day
Number of subjects: 704
Study 29429427 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening Visits (LV) delivered by nurses
Number of subjects: 0
Study 26389646 — intervention group
Group type: EXPERIMENTAL
Intervention: Operant conditioning of eye gaze toward happy faces (train-happy)
Number of subjects: 32
Study 26389646 — intervention group
Group type: COMPARATOR
Intervention: Operant conditioning of eye gaze toward neutral faces (train-neutral)
Number of subjects: 32
Study 24847084 — intervention group
Group type: EXPERIMENTAL
Intervention: Online spaced-education (SE) game; 87% completion rate (48/55 clinicians).
Number of subjects: 111
Study 24847084 — intervention group
Group type: COMPARATOR
Intervention: Control group received identical educational content in an online posting; 84% reading rate (47/56 clinicians).
Number of subjects: 111
Study 22397987 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg wound drain (size 10 high vacuum, 20 kPa)
Number of subjects: 100
Study 22397987 — intervention group
Group type: COMPARATOR
Intervention: No leg wound drain
Number of subjects: 100
Study 22397987 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg wound drain
Number of subjects: 100
Study 22397987 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 20552088 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsubmerged healing
Number of subjects: 29
Study 20552088 — intervention group
Group type: COMPARATOR
Intervention: Submerged healing
Number of subjects: 29
Study 18783114 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with an infrared laser (830nm, 500mW, 20s, 4J/point), once a week for four consecutive weeks.
Number of subjects: 40
Study 18783114 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment, once a week for four consecutive weeks.
Number of subjects: 40
Study 18783114 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 40
Study 18783114 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40
Study 15599360 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser irradiation (10 Hz, 250 mJ input, 112 mJ output) with liquid adhesive (Super Bonder and Single Bond adhesive)
Number of subjects: 94
Study 15599360 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% EDTA with liquid adhesive (Super Bonder and Single Bond adhesive)
Number of subjects: 94
Study 11855313 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (norvask)
Number of subjects: 18
Study 10442192 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin with amifostine (740 mg/m2)
Number of subjects: 74
Study 10442192 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin only (70 mg/m2)
Number of subjects: 74
Study 7872933 — intervention group
Group type: EXPERIMENTAL
Intervention: Padua Inventory (PI)
Number of subjects: 858
Study 2240628 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N2O) added to isoflurane anesthesia (50%-60%)
Number of subjects: 26
Study 2240628 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anesthesia without N2O
Number of subjects: 26
Study 15297 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg t.i.d.
Number of subjects: 15
Study 15297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30939592 — intervention group
Group type: EXPERIMENTAL
Intervention: d-methadone (single doses up to 150 mg)
Number of subjects: 2
Study 30939592 — intervention group
Group type: EXPERIMENTAL
Intervention: d-methadone (daily doses up to 75 mg for 10 days)
Number of subjects: 2
Study 30939592 — intervention group
Group type: EXPERIMENTAL
Intervention: d-methadone (higher dose levels)
Number of subjects: 2
Study 30939592 — intervention group
Group type: EXPERIMENTAL
Intervention: d-methadone (various doses)
Number of subjects: 2
Study 30939592 — intervention group
Group type: EXPERIMENTAL
Intervention: d-methadone (higher doses)
Number of subjects: 2
Study 30939592 — intervention group
Group type: EXPERIMENTAL
Intervention: d-methadone (60 mg or above)
Number of subjects: 2
Study 30939592 — intervention group
Group type: EXPERIMENTAL
Intervention: d-methadone
Number of subjects: 2
Study 30939592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 28515098 — intervention group
Group type: EXPERIMENTAL
Intervention: Procollagen type III N‐terminal propeptide (PIIINP)
Number of subjects: 3068
Study 28515098 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen type I carboxy-terminal telopeptide (ICTP)
Number of subjects: 3068
Study 25607118 — intervention group
Group type: EXPERIMENTAL
Intervention: LifeWave Energy Enhancer (LEE) patches
Number of subjects: 20
Study 25607118 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 20
Study 23506291 — intervention group
Group type: EXPERIMENTAL
Intervention: Peach pulp
Number of subjects: 57
Study 23506291 — intervention group
Group type: COMPARATOR
Intervention: Peach peel
Number of subjects: 57
Study 23506291 — intervention group
Group type: COMPARATOR
Intervention: Peach lipid transfer protein (LTP)
Number of subjects: 57
Study 23506291 — intervention group
Group type: COMPARATOR
Intervention: Profilin
Number of subjects: 57
Study 23506291 — intervention group
Group type: COMPARATOR
Intervention: Serum-specific IgE to peach
Number of subjects: 57
Study 23506291 — intervention group
Group type: COMPARATOR
Intervention: rPru p 3-specific IgE
Number of subjects: 57
Study 23506291 — intervention group
Group type: COMPARATOR
Intervention: rPru p 1-specific IgE
Number of subjects: 57
Study 23506291 — intervention group
Group type: COMPARATOR
Intervention: rPru p 4-specific IgE
Number of subjects: 57
Study 21681064 — intervention group
Group type: EXPERIMENTAL
Intervention: TreSPE treatment (treadmill training, stretching, respiratory, and proprioceptive exercise) twice a week for 8 weeks
Number of subjects: 8
Study 21681064 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 8
Study 21681064 — intervention group
Group type: EXPERIMENTAL
Intervention: TreSPE treatment
Number of subjects: 8
Study 19224764 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with procarbazine, lomustine, and vincristine
Number of subjects: 368
Study 19224764 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaplastic oligodendroglial tumors with EGFR(amp)
Number of subjects: 368
Study 19224764 — intervention group
Group type: EXPERIMENTAL
Intervention: AOA with necrosis
Number of subjects: 368
Study 19224764 — intervention group
Group type: EXPERIMENTAL
Intervention: AOA with only endothelial proliferation
Number of subjects: 368
Study 19224764 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular factors analyzed
Number of subjects: 368
Study 16426083 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose sertraline (250-400 mg/day, mean final dose = 357 mg, SD = 60)
Number of subjects: 66
Study 16426083 — intervention group
Group type: COMPARATOR
Intervention: Standard sertraline (200 mg/day)
Number of subjects: 66
Study 14568832 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser pretreatment plus 4% lidocaine cream
Number of subjects: 320
Study 14568832 — intervention group
Group type: COMPARATOR
Intervention: Laser pretreatment plus placebo
Number of subjects: 320
Study 14568832 — intervention group
Group type: COMPARATOR
Intervention: 4% lidocaine cream alone
Number of subjects: 320
Study 11144048 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoinhal Dermatophagoides
Number of subjects: 17
Study 11144048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 8867360 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative electric field stimulation
Number of subjects: 17
Study 8867360 — intervention group
Group type: COMPARATOR
Intervention: No electric field stimulation (Control)
Number of subjects: 17
Study 1513920 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 to 5 mg per day of oral haloperidol
Number of subjects: 19
Study 6468201 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour cover with metronidazole and gentamicin
Number of subjects: 0
Study 6468201 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged use of metronidazole and gentamicin for five days
Number of subjects: 0
Study 6468201 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis with 24-hour cover with metronidazole and five-day therapy with mezlocillin
Number of subjects: 0
Study 6468201 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour cover with metronidazole and five-day exposure to latamoxef
Number of subjects: 0
Study 6468201 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 28950157 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based multicomponent treatment (GMT)
Number of subjects: 158
Study 28950157 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 158
Study 27470620 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine
Number of subjects: 130
Study 27470620 — intervention group
Group type: COMPARATOR
Intervention: Entecavir
Number of subjects: 130
Study 24813065 — intervention group
Group type: EXPERIMENTAL
Intervention: L-methylfolate 15 mg/d for 60 days
Number of subjects: 75
Study 24813065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 22914396 — intervention group
Group type: EXPERIMENTAL
Intervention: Pessary therapy
Number of subjects: 446
Study 22914396 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Number of subjects: 446
Study 22914396 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 446
Study 22914396 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical therapy
Number of subjects: 446
Study 20123872 — intervention group
Group type: EXPERIMENTAL
Intervention: ViziLite
Number of subjects: 258
Study 20123872 — intervention group
Group type: EXPERIMENTAL
Intervention: VELscope
Number of subjects: 258
Study 17067621 — intervention group
Group type: EXPERIMENTAL
Intervention: Mason-Likar (ML) 12-lead ECG
Number of subjects: 88
Study 17067621 — intervention group
Group type: EXPERIMENTAL
Intervention: EASI-derived 12-lead ECG
Number of subjects: 88
Study 17067621 — intervention group
Group type: COMPARATOR
Intervention: 12-lead ECG acquired in clinical practice (CP)
Number of subjects: 88
Study 15685511 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma IL-6 levels
Number of subjects: 206